⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 14, 2024

[Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world].

Qingyan Gao B Li S Q Qu L J Pan Meng Jiao Jie Zhao Zefeng Xu Zhijian Xiao T J Qin

View at Publisher

Ask AI

Bookmark

Share

Abstract

To investigate the efficacy and safety of combining venetoclax (VEN) with hypomethylated drugs (HMA) in the treatment of higher-risk (IPSS-R score >3.5) myelodysplastic syndromes (MDS) .

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gao et al. (2024) studied this question.

synapsesocial.com/papers/68e7941db6db6435877058f6 https://doi.org/10.3760/cma.j.cn121090-20230926-00136

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1[Efficacy and safety of venetoclax combined with hypomethylating agents in the treatment of 83 patients with higher-risk myelodysplastic syndromes].2024
2A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients2024 · 2 citations
3Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE databaseLate-Phase Clinical Trial · 2026 · 3 citations
4Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort StudyHuman Clinical Trial · 2026
5Real-World Outcomes of Hypomethylating Agents and Venetoclax Combination Therapy in AML and Myelodysplastic Syndrome in PakistanRetrospective Study · 2026 · 1 citations

More related papers

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study2024
Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience2026
Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025